Search Results
Your search for ,WHo matches 20416 pages
Showing 5701 - 5750Sidney Kimmel Cancer Center–Jefferson Health Names Andrew Aplin, PhD, Deputy Director for Scientific Strategy
Andrew E. Aplin, PhD, has been appointed Deputy Director for Scientific Strategy of the Sidney Kimmel Cancer Center (SKCC)–Jefferson Health. Dr. Aplin, who is Associate Director for Basic Research at SKCC and the Kalbach-Newton Professor in Cancer Research, assumed the role on June 1, 2021. As...
NIH Names Marie A. Bernard, MD, Chief Officer for Scientific Workforce Diversity
National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, has selected Marie A. Bernard, MD, as NIH’s next Chief Officer for Scientific Workforce Diversity (COSWD). Dr. Bernard will lead NIH’s effort to promote diversity, inclusiveness, and equity throughout the biomedical research...
CheckMate 648: First-Line Nivolumab Regimens Improve Survival in Esophageal Squamous Cell Carcinoma
As first-line treatment of advanced esophageal squamous cell carcinoma, nivolumab-containing regimens improved overall survival over standard-of-care chemotherapy, according to the first results of the global phase III CheckMate 648 trial presented at the 2021 ASCO Annual Meeting by Ian Chau, MD,...
Expert Point of View: Kunle Odunsi, MD, PhD, and Lilian T. Gien, MD, MSc
Comments on the OUTBACK trial were provided by invited discussant Kunle Odunsi, MD, PhD, Professor of Obstetrics and Gynecology, Dean for Oncology, and Director of the University of Chicago Medicine Comprehensive Cancer Center. Lilian T. Gien, MD, MSc, Associate Professor of Oncology at the...
Gauri Varadhachary, MD, Compassionate Leader, Caring and Brilliant Physician, Dies at 52
Gauri Varadhachary, MD, Clinical Professor in Gastrointestinal (GI) Medical Oncology at The University of Texas MD Anderson Cancer Center, died on June 5, 2021. She was 52. A member of the MD Anderson community for nearly 20 years, Dr. Varadhachary was remembered for her dedication to her patients, ...
Dana-Farber and Harvard Street Neighborhood Health Center to Connect Patients to Cancer Services
Dana-Farber Cancer Institute and Harvard Street Neighborhood Health Center (HSNHC) in Dorchester, Massachusetts, have entered into an agreement to connect patients to cancer prevention, education, diagnosis, and treatment services. This program, based out of Dana-Farber’s Cancer Care Equity...
Addressing Sexuality Challenges Throughout the Cancer Care Continuum
Multiple studies have shown that sexuality and intimacy problems are common among patients with cancer, often beginning at the time of diagnosis and persisting through the continuum of care into the survivorship setting. Although these problems have been well documented, many patients and survivors ...
Pancreatic Cancer Center of Excellence to Leverage Research and Clinical Care Innovations for Patients
The University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has established the Pancreatic Cancer Center of Excellence to bring together cancer center faculty with a broad range of expertise—from laboratory, translational, and clinical research to drug development, biostatistics,...
John D. Carpten, PhD, FAACR, to Join the AACR Board of Directors
The American Association for Cancer Research (AACR) recently announced that John D. Carpten, PhD, FAACR, has been elected by the association to serve on its Board of Directors. Dr. Carpten has accepted the position previously held by Karen E. Knudsen, MBA, PhD, who is stepping down to fulfill her...
Newly Diagnosed Multiple Myeloma
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on...
Innovator in Treatment of Infectious Diseases, Francisco Marty, MD, Dies at 53
The Brigham and Women’s hospital community mourns the loss of Francisco Marty, MD, of the Division of Infectious Diseases, who died April 8, 2021, after a tragic accident while hiking in the Dominican Republic. He was 53. A member of the Brigham community for more than 20 years, Dr. Marty is...
OUTBACK: No Benefit for Adjuvant Chemotherapy in Cervical Cancer
In women with locally advanced cervical cancer, adjuvant chemotherapy adds no benefit to standard cisplatin-based chemoradiation, results of the international phase III OUTBACK study have shown,1 as reported at the 2021 ASCO Annual Meeting by Linda R. Mileshkin, MD, Professor of Medical Oncology at ...
Do Community Oncologists Have Access to Geriatric Specialty Care for Older Patients?
As our population rapidly ages, the burden of cancer incidence increases accordingly, creating an urgent need for greater and more incisive research on the diagnosis, treatment, and survivorship issues for older adults with cancer. Given the numerous challenges faced by today’s busy oncologists, a...
KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
Cancer in Morocco: Access to Innovative Treatments and Research Status
Morocco is an Arab country in North Africa. It covers 716,550 square kilometers and has a population of nearly 36 million. The median age is 29.3 years. Morocco’s estimated gross domestic product (GDP) in 2019 was $122 million. As of 2019, Morocco’s health budget was equivalent to 4.5% of the total ...
Whispers Over My Shoulder
When I interviewed for my current post as a first-time consultant in medical oncology in the United Kingdom, I was asked about my 5-year career plan. I remember some detail of my reply, but I don’t think it even remotely encompassed the depth of insight I would gain from the patients I’ve treated...
Cynthia M. Yoshida, MD, Honored Nationally for Increasing Colorectal Cancer Screening Rates
Cynthia M. Yoshida, MD, is one of six winners of a national award recognizing health-care providers and institutions for their work to increase colorectal cancer screening rates. Dr. Yoshida, a gastroenterologist and medical leader of the University of Virginia (UVA) Cancer Center’s Colorectal...
Mary Daly, MD, PhD, FACP, Receives NCCN’s 2021 Rodger Winn Award
The National Comprehensive Cancer Network (NCCN) recently presented Mary B. Daly, MD, PhD, FACP, Professor in the Department of Clinical Genetics and Director of the Risk Assessment Program at Fox Chase Cancer Center, with the Rodger Winn Award. The Rodger Winn Award is given annually to one NCCN...
Harnessing a Worldwide Effort to Combat COVID-19 and Cancer
This past October, in a virtually held ceremony of the General Assembly of the Union for International Cancer Control (UICC), Anil K. D’Cruz, MBBS, MS, DNB, FRCS (Hon), Director of Oncology at Apollo Hospitals in Mumbai, Chennai, and Delhi, India, began his 2-year tenure as President of the global...
Sotorasib: Subgroup Analysis of Phase II Trial Shows Activity With Breakthrough KRAS Inhibitor in Lung Cancer
The breakthrough KRAS-specific inhibitor sotorasib achieved responses in patients with KRAS G12C–mutated non–small lung cancer (NSCLC) who had experienced disease progression on platinum-based chemotherapy, immunotherapy, or both treatments. The objective response rate was 37.1%, and responses...
How RAS Mutations in Early-Onset Colorectal Cancer May Impact Patient Survival
Although both incidence and mortality rates in colorectal cancer have been declining among people older than 65 by 3.3% and 3% annually, respectively, among individuals younger than age 50, the incidence rate has risen about 2% annually, and death rates have increased by 1.3% annually.1 Colorectal...
Expert Point of View: Nadine M. Tung, MD
Formal discussant of OlympiA, Nadine M. Tung, MD, Director of Breast Medical Oncology and the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center and Harvard Medical School, was enthusiastic about the ability of olaparib to improve invasive disease–free survival and...
Lessons From Pneumococcal Vaccine Responses in Patients With CLL in an Evolving Vaccine Landscape
The role of vaccines in mitigating the significant morbidity and mortality associated with infections in chronic lymphocytic leukemia (CLL) is a developing field of study, punctuated by the advent of novel therapeutic agents and pressing questions regarding the global SARS–CoV-2 vaccination...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
Low Response Rates to Conjugate Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia
In an Italian study reported in Leukemia, Francesca Romana Mauro, MD, of the Department of Translational and Precision Medicine, Sapienza University, Rome, and colleagues found that only a small minority of patients with chronic lymphocytic leukemia (CLL) developed an adequate immune response to...
Expert Point of View: Sarah Blair, MD, FACS
Session moderator during the 2021 American Society of Breast Surgeons Annual Meeting, Sarah Blair, MD, FACS, Vice Chair of Academic Affairs for the Department of Surgery at University of California San Diego, urged widespread dissemination of these survey findings. “I was struck by how important...
Ruben A. Mesa, MD, on Myelofibrosis, Transfusion Independence, and Momelotinib
Ruben A. Mesa, MD, of UT Health San Antonio Cancer Center, discusses new findings on momelotinib, a potent JAK1, JAK2, and ACVR1 inhibitor with clinical activity against hallmark features of myelofibrosis such as anemia and splenomegaly. Results showed that transfusion independence was associated...
Philippe Moreau, MD, on Newly Diagnosed Multiple Myeloma: Daratumumab Maintenance vs Observation
Philippe Moreau, MD, of University Hospital Hôtel-Dieu, discusses findings from the CASSIOPEIA trial, Part 1, on daratumumab maintenance vs observation in patients with newly diagnosed multiple myeloma who have been treated with bortezomib, thalidomide, and dexamethasone, with or without...
Martin Kaiser, MD, on Myeloma and Plasma Cell Leukemia: Transplantation Plus Daratumumab/CVRD Therapy
Martin Kaiser, MD, of The Institute of Cancer Research and Royal Marsden Hospital, discusses findings from the UK OPTIMUM/MUKNINE trial on the depth of response and minimal residual disease status in patients with ultra-high–risk newly diagnosed multiple myeloma and plasma cell leukemia who were...
Study Explores Taste and Smell Dysfunction in Head and Neck Cancer Survivors
Most survivors of head and neck squamous cell cancers report that their sense of taste is dulled, changed, or lost during radiation treatment. In a study of taste and smell dysfunction in 40 cancer survivors, scientists found that the tips of these individuals' tongues were significantly less...
Study Finds Patients With Bladder Cancer and Ureteric Obstruction May Safely Receive Chemotherapy
A study published by Strother et al in BJU International found that patients with muscle-invasive bladder cancer can safely receive cisplatin-based neoadjuvant chemotherapy, even when their tumors are blocking their kidneys. The findings suggest that patients with the most serious type of this...
Survival of Patients With Colon Cancer Enrolled in the U.S. Military Health System
A study by Lin et al comparing patients with colon cancer enrolled in the U.S. Military Health System, which provides universal health-care to its beneficiaries, with those in the general population has found that patients in the Military Health System had an 18% lower risk of death compared with...
Convalescent Plasma Therapy for Patients With Hematologic Cancers Hospitalized for COVID-19
In a retrospective cohort study reported in JAMA Oncology, Michael A. Thompson, MD, PhD, FASCO, and colleagues found that the use of convalescent plasma therapy was associated with improved 30-day mortality among patients with hematologic cancers hospitalized for COVID-19. Study Details The study...
FDA Pipeline: Priority Reviews in Multiple Myeloma, Cervical Cancer, Neutropenia, and Myelofibrosis
Over the past month, the U.S. Food and Drug Administration (FDA) has granted Priority Review to therapies for multiple myeloma, cervical cancer, chemotherapy-induced neutropenia, and myelofibrosis. The FDA also granted a number of Breakthrough Therapy designations, including those for treatments in ...
Overall Survival With the Addition of Ixazomib to Lenalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma
As reported in the Journal of Clinical Oncology by Paul G. Richardson, MD, and colleagues, the final overall survival analysis of the phase III TOURMALINE-MM1 trial showed no overall survival benefit with the addition of ixazomib to lenalidomide/dexamethasone (Rd) in relapsed or refractory multiple ...
Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy
Priya Rastogi, MD, of the University of Pittsburgh, discusses results from the NRG Oncology/NSABP B-42 trial, which evaluated the utility of the 70-gene MammaPrint assay in predicting the benefit of extended letrozole therapy in patients who had completed 5 years of adjuvant endocrine therapy...
Matt D. Galsky, MD, on Bladder Cancer: Neoadjuvant Therapy With Gemcitabine, Cisplatin, and Nivolumab
Matt D. Galsky, MD, of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, discusses results from a phase II trial designed to test gemcitabine and cisplatin plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to better predict benefit in...
Study Evaluates Residential Racial Segregation and NSCLC Treatment and Outcomes
Non–small cell lung cancer (NSCLC) accounts for 80% to 85% of cases of lung cancer; when it is diagnosed early, there is a 5-year survival rate of 50% to 80%. Black patients have a lower overall incidence of NSCLC than White patients but are more likely to be diagnosed at later stages. They also...
Phase II Study of Naratuximab Emtansine Plus Rituximab in DLBCL
Adding the antibody-drug conjugate naratuximab emtansine to rituximab resulted in favorable overall survival and complete response rates for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a manageable safety profile. These findings from a phase II study were...
ASCO/Friends of Cancer Research Joint Position Statement Encourages Enrollment of Patients With Cancer in COVID-19 Vaccine Studies
Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, ASCO and Friends of Cancer Research (Friends) asserted in a joint position statement released today. To date, clinical trials...
Is Lenvatinib Plus Pembrolizumab an Effective Treatment for Patients With Metastatic Renal Cell Carcinoma?
As reported in The Lancet Oncology by Chung-Han Lee, MD, and colleagues, findings in a cohort of the phase Ib/II Study 111/KEYNOTE-146 trial showed that the combination of lenvatinib and pembrolizumab produced high response rates among patients with metastatic clear cell renal cell carcinoma...
Brexucabtagene Autoleucel in Adults With Relapsed or Refractory B-Cell ALL: ZUMA-3
As reported in The Lancet by Shah et al, the pivotal phase II ZUMA-3 trial has shown a high rate of complete remission with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (formerly KTE-X19) in adults with relapsed or refractory B-cell acute...
Testing of Lymph Nodes for Breast Cancer Recurrence After Neoadjuvant Chemotherapy
A study published by Sharp et al in The Breast Journal suggests that some patients with breast cancer may be able to forgo certain testing procedures after neoadjuvant chemotherapy without increasing their risk of cancer recurrence. Prior studies on detecting whether breast cancer has spread to...
Addition of Isatuximab-irfc to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma: IKEMA Trial
As reported in The Lancet by Philippe Moreau, MD, and colleagues, the phase III IKEMA trial has shown that the addition of the anti-CD38 antibody isatuximab-irfc to carfilzomib and dexamethasone resulted in significantly improved progression-free survival in patients with relapsed or refractory...
Prevalence of Germline BRCA Mutations in Women With Ovarian Cancer in India
In a prospective cross-sectional study reported in JCO Global Oncology, Gupta et al found that women with ovarian cancer in India had a high prevalence of pathogenic or likely pathogenic BRCA variants. As stated by the investigators: “There are deficient data on prevalence of germline mutations in...
Survivors of Early-Stage Breast Cancer Face Broad Range of Symptoms and Concerns
Patients with early-stage breast cancer may be at low risk of dying of their disease, but they experience a high burden of physical and psychological symptoms long after their treatment has ended, according to data presented during the 2021 American Society of Breast Surgeons Annual Meeting.1...
Retrospective Study Explores Variation in Colorectal Cancer Risk in Families With Lynch Syndrome
In a retrospective cohort study reported by Win et al in The Lancet Oncology, researchers in the International Mismatch Repair Consortium found marked variation in the risk of colorectal cancer in families with Lynch syndrome carrying the same pathogenic variant in DNA mismatch repair genes. The...
All-Cause Mortality in COVID-19–Positive and COVID-19–Negative Patients With Cancer
In a large cohort study reported by Sharafeldin et al in the Journal of Clinical Oncology, researchers from the National COVID Cohort Collaborative (N3C) found that COVID-19–positive vs –negative status was associated with an increased risk of all-cause mortality at 1 year among patients with...
Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response
Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of...
Expert Point of View: Anthony TC Chan, MD
The invited discussant of the JUPITER-02 study was Anthony TC Chan, MD, the Li Shu Fan Medical Foundation Professor of Clinical Oncology at Hong King Cancer Institute and Sir YK Pao Centre for Cancer at the Chinese University of Hong Kong. He noted that anti–PD-1/L1 therapies are at the forefront...
